EPH85 Real-World Temporal and Indication-Specific Variation in Drivers of GLP-1 RA DiscontinuationB Cartwright, N. Stucky, Patricia J. Rodriguez et al.|Value in Health|2025Cited by 0
HPR108 Trends in the Prescribing and Dispensing of GLP-1 Anti-Obesity Medications Among U.S. Adults with Cardiovascular Disease and Overweight or Obesity, 2021-2024Duy Do, N. Stucky, Lesley H. Curtis et al.|Value in Health|2025Cited by 0
EPH49 Characteristics and Adherence of Patients Initiating Injectable Cabotegravir for HIV Treatment or PreventionDuy Do, N. Stucky, B Cartwright et al.|Value in Health|2025Cited by 0